UBS Maintains Buy on American Healthcare REIT, Lowers Price Target to $62
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
UBS analyst Michael Goldsmith maintains American Healthcare REIT (NYSE:AHR) with a Buy and lowers the price target from $63 to $62.
UBS analyst Michael Goldsmith maintains American Healthcare REIT (NYSE:AHR) with a Buy and lowers the price target from $63 to $62.